Responses
Late-breaking abstracts
Clinical trials completed
794 Safety and efficacy results from a phase 1/1b study of intratumoral MK-4621, a retinoic acid-inducible gene I (RIG-I) agonist, plus intravenous pembrolizumab in patients with advanced solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
